Blue Cross Blue Shield
Jan 31, 2019
Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly rushed its deal
Voyager clears Neurocrine agreement for Parkinson's gene therapy Voyager Therapeutics is signing a collaboration agreement with Neurocrine Biosciences that will remunerate the Cambridge, Massachusetts-based biotech USD 165 million upfront. In return, Neurocrine benefits certain rights to four gene therapy progra...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
